Skip to Main Content

This is not just another shareholder revolt.

Mylan, which sells EpiPen, holds its annual shareholder meeting in the Netherlands on Thursday. And several large pension funds are working publicly — and also behind the scenes — to push out key directors, starting with Robert Coury, the controversial non-executive chairman, and Heather Bresch, the chief executive officer.


But much more is at stake than unhappy investors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!